Q1 EPS Estimates for Stoke Therapeutics Raised by Wedbush

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Equities researchers at Wedbush raised their Q1 2025 earnings per share estimates for Stoke Therapeutics in a report issued on Tuesday, January 7th. Wedbush analyst L. Chico now anticipates that the company will post earnings of ($0.56) per share for the quarter, up from their prior estimate of ($0.59). The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.03) per share. Wedbush also issued estimates for Stoke Therapeutics’ Q2 2025 earnings at ($0.49) EPS, Q3 2025 earnings at ($0.51) EPS, Q4 2025 earnings at ($0.52) EPS, FY2025 earnings at ($2.08) EPS, FY2026 earnings at ($2.32) EPS, FY2027 earnings at ($2.53) EPS and FY2028 earnings at ($2.27) EPS.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.47) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.05. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. The firm had revenue of $4.89 million for the quarter, compared to the consensus estimate of $3.46 million.

Several other equities analysts have also weighed in on STOK. HC Wainwright restated a “buy” rating and set a $35.00 target price on shares of Stoke Therapeutics in a report on Wednesday. Leerink Partners began coverage on Stoke Therapeutics in a report on Monday, October 14th. They set an “outperform” rating and a $18.00 price objective on the stock. Chardan Capital assumed coverage on Stoke Therapeutics in a report on Friday, December 20th. They set a “buy” rating and a $24.00 price objective on the stock. Leerink Partnrs upgraded shares of Stoke Therapeutics to a “strong-buy” rating in a research note on Friday, October 11th. Finally, Needham & Company LLC restated a “buy” rating and issued a $22.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday. One analyst has rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Stoke Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $21.29.

Stoke Therapeutics Stock Up 0.4 %

STOK opened at $9.00 on Friday. The firm has a market cap of $476.70 million, a PE ratio of -4.29 and a beta of 0.95. The business has a fifty day simple moving average of $11.91 and a 200-day simple moving average of $13.04. Stoke Therapeutics has a fifty-two week low of $4.09 and a fifty-two week high of $17.58.

Hedge Funds Weigh In On Stoke Therapeutics

A number of large investors have recently modified their holdings of the company. Quest Partners LLC purchased a new position in shares of Stoke Therapeutics in the 2nd quarter valued at approximately $29,000. Intech Investment Management LLC purchased a new position in Stoke Therapeutics during the third quarter valued at $160,000. The Manufacturers Life Insurance Company lifted its stake in shares of Stoke Therapeutics by 16.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 13,964 shares of the company’s stock valued at $189,000 after buying an additional 1,994 shares in the last quarter. Mesirow Financial Investment Management Inc. bought a new stake in shares of Stoke Therapeutics during the third quarter valued at approximately $192,000. Finally, Profund Advisors LLC bought a new position in shares of Stoke Therapeutics during the 2nd quarter valued at approximately $201,000.

Insider Transactions at Stoke Therapeutics

In other Stoke Therapeutics news, CEO Edward M. Md Kaye sold 6,786 shares of the business’s stock in a transaction on Monday, December 9th. The stock was sold at an average price of $12.99, for a total value of $88,150.14. Following the sale, the chief executive officer now directly owns 61,885 shares in the company, valued at $803,886.15. The trade was a 9.88 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Barry Ticho sold 10,000 shares of the company’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $12.07, for a total value of $120,700.00. Following the sale, the insider now owns 51,277 shares in the company, valued at approximately $618,913.39. This represents a 16.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 62,849 shares of company stock worth $809,421. Company insiders own 11.30% of the company’s stock.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.